In the HER2 OE NSCLC pretreated patients (n = 22), the ORR was 54.5%, mDoR was 20.2 months, and mPFS was 15.1 months; in the naive patients (n = 8), ORR was 62.5%, mDoR was 20.2 months, and mPFS was 23.5 months. Here, ERBB2 is linked to non-small cell lung carcinoma.